Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azathioprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azathioprine SCHEMBL4278 | 1.00 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL29693611 | 1.00 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL26152 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL317904 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL502599 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL3089846 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4259183 | 0.92 | MAPT (0.84) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8354969 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8511946 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL2328735 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114729354-A | Small RNA medicine for preventing and treating inflammatory related diseases and combination thereof | 中国医学科学院基础医学研究所 | 2022-07-08 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2020132844-A1 | SMALL RNA MEDICAMENT FOR PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISEASES AND COMBINATION THEREOF | 中国医学科学院基础医学研究所 | 2020-07-02 | — | — | WO | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-102764436-A | Treatment of TNF alpha related disorders | ABBOTT BIOTECH LTD | 2012-11-07 | — | — | CN | disclosed |
| CN-102755646-A | Medicament for treating TNF alpha related disorder | ABBOTT BIOTECH LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101745112-A | Treatment of TNFalpha related disorders | ABBOTT BIOTECH LTD | 2010-06-23 | — | — | CN | disclosed |
| EP-2068865-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | Limerick BioPharma, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008083160-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| CN-1720224-A | Vascular balancing agents and methods of use thereof | TARGEGEN INC (US) | 2006-01-11 | — | — | CN | disclosed |
| CN-1691963-A | Treatment of TNF alpha related diseases | ABBOTT BIOTECH LTD (BM) | 2005-11-02 | — | — | CN | disclosed |